Withdrawals due to adverse events · children with juvenile idiopathic arthritis and flat feet
Custom foot orthoses showed no clear difference in withdrawal due to adverse events compared with prefabricated foot orthoses (low certainty).
1 finding from 1 review
RR 0.8 [0.13, 4.87]
Studies not reported
Low
Adverse effects · children with juvenile idiopathic arthritis and flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · children with juvenile idiopathic arthritis and flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant‐reported improvement in sialorrhea in the short term · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via gastrostomy and most…
1 finding from 1 review
no estimate extracted
8 participants
Very low
Reduction in the amount of saliva production in the short term using an objective measure · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via gastrostomy and most…
1 finding from 1 review
no estimate extracted
8 participants
Very low
Quality of life · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via gastrostomy and most…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via gastrostomy and most…
1 finding from 1 review
no estimate extracted
10 participants
Very low
Fatal or nonfatal myocardial infarction · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents probably leads to lower fatal or nonfatal myocardial infarction compared with control (moderate certainty).
1 finding from 1 review
Fatal or nonfatal stroke · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
It is very uncertain whether antiplatelet agents changes fatal or nonfatal stroke compared with control (very low certainty).
1 finding from 1 review
Death (any cause) · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents showed no clear difference in death (any cause) compared with control (low certainty).
1 finding from 1 review
Cardiovascular mortality · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
It is very uncertain whether antiplatelet agents changes cardiovascular death compared with control (very low certainty).
1 finding from 1 review
Major bleeding · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents probably leads to higher major bleeding compared with control (moderate certainty).
1 finding from 1 review
Minor bleeding · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents may leads to higher minor bleeding compared with control (low certainty).
1 finding from 1 review
Early access thrombosis (before 8 weeks) · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents may leads to lower early access thrombosis (before 8 weeks) compared with control (low certainty).
1 finding from 1 review
Primary outcome 1: Number of clinical recurrences per participant per year · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
1 finding from 1 review
Primary outcome 2: Clinical recurrence at 6 months · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
Drug treatment may leads to lower primary outcome 2: Clinical recurrence at 6 months compared with placebo or no treatment (low certainty).
1 finding from 1 review
Recurrence · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
Drug treatment may leads to lower primary outcome 2: Clinical recurrence at 12 months compared with placebo or no treatment (low certainty).
1 finding from 1 review
Primary outcome 3: Adverse events · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
1 finding from 1 review
Primary outcome 1: Number of clinical recurrences per participant per year · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
1 finding from 1 review
Primary outcome 2: Clinical recurrence at 6 months · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
It is very uncertain whether oral drug treatment changes primary outcome 2: Clinical recurrence at 6 months compared with topical drug treatment (very low certainty).
1 finding from 1 review